GlassScriptPhysician profile
Dilruba N Haque
NPI 1689838641
$11,893.41
in general payments reported to CMS, 2019-2025
69 companies · $3,718 in 2025
The $3,718 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,279 · 2020: $1,781 · 2021: $1,103 · 2022: $15.68 · 2023: $360 · 2024: $3,637 · 2025: $3,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,425 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,425.20 |
| Education | $289.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $805.45 | 2019-2025 | |
| Pfizer INC. | $784.82 | 2019-2025 | |
| Janssen Biotech, INC. | $675.98 | 2019-2025 | Erleada, Darzalex, Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $639.98 | 2019-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $596.59 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Eisai INC. | $496.86 | 2020-2025 | |
| Glaxosmithkline, LLC. | $477.21 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Astrazeneca Pharmaceuticals LP | $439.78 | 2019-2025 | Tagrisso, Enhertu, Imfinzi |
| Amgen INC. | $434.84 | 2019-2021 | |
| Daiichi Sankyo INC. | $403.32 | 2019-2025 | Enhertu |
| Incyte Corporation | $363.01 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Pharmacyclics LLC, An Abbvie Company | $325.60 | 2019-2023 | Imbruvica |
| Bayer Healthcare Pharmaceuticals INC. | $311.44 | 2019-2025 | |
| Astellas Pharma US INC | $283.48 | 2024-2025 | Vyloy, Xtandi, Padcev |
| Emd Serono, INC. | $266.41 | 2019-2024 |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $256.36 | 2019-2025 | Reblozyl, Opdualag, Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $250.08 | 2023-2025 | Ninlaro, Fruzaqla |
| Genzyme Corporation | $239.50 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $212.14 | 2020-2024 | Ultomiris |
| Karyopharm Therapeutics INC. | $207.21 | 2020-2025 | Xpovio |
| Stemline Therapeutics INC. | $182.03 | 2024-2025 | Orserdu |
| Lilly USA, LLC | $177.58 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Exelixis INC. | $171.56 | 2019-2024 | Cabometyx |
| Puma Biotechnology, INC. | $171.26 | 2019-2025 | |
| Genentech USA, INC. | $160.98 | 2019-2025 | Tecentriq, Itovebi, Polivy |
| Sobi, INC | $154.03 | 2024-2025 | |
| Abbvie INC. | $149.94 | 2019-2025 | |
| Gilead Sciences, INC. | $146.89 | 2019-2025 | Trodelvy |
| Aveo Pharmaceuticals, INC. | $141.76 | 2023-2025 | Fotivda |
| Beigene USA, INC. | $121.33 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.68 | 2020-2025 | |
| Array Biopharma INC | $111.59 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Ipsen Biopharmaceuticals, INC | $104.73 | 2021-2025 | Somatuline Depot, Onivyde |
| Rigel Pharmaceuticals, INC. | $101.25 | 2024-2025 | Rezlidhia, Gavreto, Tavalisse |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Coherus Oncology, INC. | $81.62 | 2020-2025 | Loqtorzi |
| Pharmaessentia USA Corporation | $77.77 | 2024-2025 | Besremi |
| Janssen Pharmaceuticals, INC | $75.84 | 2020-2021 | |
| Taiho Oncology, INC. | $73.90 | 2019-2024 | |
| Cumberland Pharmaceuticals, INC. | $71.34 | 2024-2025 | Sancuso |
| Sun Pharmaceutical Industries INC. | $71.32 | 2024 | |
| Kite Pharma, INC. | $65.04 | 2020-2021 | |
| Seagen INC. | $63.54 | 2019-2021 | |
| Blueprint Medicines Corporation | $60.24 | 2020-2025 | Ayvakit |
| Tesaro, INC. | $56.99 | 2019 | |
| Amag Pharmaceuticals, INC. | $46.17 | 2020-2021 | |
| Springworks Therapeutics, INC. | $45.64 | 2024 | Ogsiveo |
| Clovis Oncology, INC. | $38.83 | 2020 | |
| Mirati Therapeutics, INC. | $36.46 | 2023-2024 | Krazati |
| Adc Therapeutics America, INC. | $32.73 | 2024 | |
| Verity Pharmaceuticals INC. | $31.87 | 2025 | Trelstar |
| Progenics Pharmaceuticals, INC. | $29.54 | 2025 | |
| Beone Medicines USA, INC. | $28.84 | 2025 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $26.34 | 2025 | Monoferric |
| Secura Bio, INC. | $25.51 | 2020 | |
| Deciphera Pharmaceuticals INC. | $23.79 | 2025 | Romvimza, Qinlock |
| Sumitomo Pharma America, INC. | $23.61 | 2024 | Orgovyx |
| Regeneron Healthcare Solutions, INC. | $23.25 | 2025 | Libtayo |
| Myovant Sciences INC. | $22.65 | 2021 | |
| Geron Corporation | $22.15 | 2025 | Rytelo |
| Teva Pharmaceuticals USA, INC. | $22.00 | 2020 | |
| Ge Healthcare | $21.33 | 2025 | |
| Immunogen, INC. | $20.76 | 2024 | Elahere |
| Sirtex Medical INC | $17.12 | 2020 | |
| Recordati_rare_diseases_inc. | $16.40 | 2024 | Sylvant |
| Biosense Webster, INC. | $15.76 | 2020 | |
| Aurobindo Pharma USA, INC. | $14.22 | 2020 | |
| Spectrum Pharmaceuticals INC. | $13.00 | 2019 | |
| Pharmaand Gmbh | $12.18 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dilruba Haque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.